Global Multiple Myeloma Therapeutics Market
According to the report " Multiple Myeloma Therapeutics Market ", published by Market Data Forecast, the global market is projected to reach USD 9.1 Billion by 2021, at a CAGR of 4.8 % from 2016 to 2021.
Multiple myeloma remains comparatively rare, it is a deceptive disease and patients typically deplete treatment alternatives. Myeloma and MGUS are twice as common in blacks paralleled with whites and marginally more common in males than females. The Multiple Myeloma( MM) market is presently dominated by Velcade and Revlimid, and the market is set to experience considerable growth between 2016 and 2021.
Expanding indications of existing drugs, emergence of new and promising drugs, increasing incidence of multiple myeloma and increasing use of drugs already on the market are fuelling growth of the market. Factors such as varied therapeutic areas, rising investment in research and development for new therapies, increasing demand and extensive off-label use of IG are some of the foremost factors contributing to the growth of the multiple myeloma therapeutics market.
The Global Multiple Myeloma Therapeutics Market is segmented by Treatment Type, Drug Type and Geography
1. By Treatment Type: � Chemotherapy
• Anthracycline antibiotic a) Melphalan( Alkeran) b) Liposomal doxorubicin( Doxil)
• Alkylating agent a) Doxorubicin( Adriamycin) b) Cyclophosphamide( Neosar) c) Vincristine( Oncovin) d) Carmustine( BiCNU)
� Targeted therapy
• Proteasome inhibitor a) Bortezomib( Velcade) b) Carfilzomib( Kyprolis)
2. By Drug Type
� Corticosteroids
• Dexamethasone( Decadron)
• Prednisone( Deltasone / Orasone)
� Immunomodulatory agents
• Thalidomide( Thalomid)
• Lenalidomide( Revlimid)
• Arsenic trioxide( Trisenox)
• Plerixafor( Mozobil)
3. By Geography: � North America � Europe
+ 1 888-702-9626 | www. marketdataforecast. com | contact @ marketdataforecast. com